MKM Biotech invests in medical hashish startups and personalised most cancers remedy

In total, BRL 4 million will be invested in about 10 businesses by August 2023

THE MKM Biotecha venture life sciences and biotechnology investment company dedicated to making innovative medicines and products get off the ground, invested BRL 800,000 in startups remederi and Biotech Quiver who work in health sector.

In total, they will BRL 4 million invested in approx. 10 deals until August 2023.

Meet the selected startups

The first joint venture was made with remederia company whose mission is to promote quality of life through access to products, services and education about medical cannabis.

The second agreement was signed with the Biotech Quiver, startup led by researcher Vilma Regina Martins, which aims to mitigate the low efficiency of chemotherapy treatments, customizing the medicine for each person. It is estimated that 60% of the time, the first chemotherapy session does not work as planned, forcing the patient to start a new session.

In addition to the amount invested, which makes MKM Biotech a partner, with 10% of the startup, the company also performs the venture buildingproviding resources, networking and the expertise of an expert team in biotechnology and the pharmaceutical industry.

The company also has a back office structure, with areas such as: legal, accounting and marketing.

The idea is that the researcher or entrepreneur can focus on advancing their tests and products, while MKM Biotech takes care of the other aspects of the business.

Purpose of the contribution

At remederithe contributions made will aim to:

• Increased sales traction
• Accelerating marketing investments

To the Biotech Quiverthe priorities will be:

• The initial structuring of the business
• The development of the proof of concept

The MKM Biotech initiative

In addition to startups, research into new drugs, exams, vaccines, equipment, among other initiatives, preferably in the pre-clinical stage of trials, can be selected.

“The idea is that the researcher or entrepreneur can focus on advancing their tests and products, while we structure the other aspects of the business”, says MKM Biotech CEO Carlos Zago.

“Our role is to identify, invest, organize the strategy and enable the study to reach advanced stages. To reach the stage of pre-clinical tests, it is estimated a cash of R$ 2 million, per research. To achieve this goal, the startup needs to present itself well to the market and we have this expertise”, emphasizes Zago.

Source: Exam